Publications by authors named "Tampouratzi Eleftheria"
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment
Article Synopsis
- Psoriasis is a chronic condition, and switching treatment options is common for patients who don't respond well to initial therapies, particularly for those with more severe disease.
- Patients who switch biologics may develop anti-drug antibodies, which could reduce the effectiveness of future treatments.
- An observational study of five patients with severe plaque psoriasis showed that after switching from brodalumab to adalimumab and then back to brodalumab, patients experienced a significant return of efficacy, improving both skin and joint symptoms.
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Dimitrios Rigopoulos Charalampos Angelakopoulos Zoi Apalla Sophia Georgiou Florentina Delli Eleftheria Tampouratzi
Dermatol Ther
December 2022
Article Synopsis
- Brodalumab has shown significant clinical effectiveness and a good safety record in controlled trials, but limited real-world data exists; the BrIDGE study in Greece aims to fill this gap by observing treatment outcomes in moderate-to-severe plaque psoriasis patients over 104 weeks.* -
- Early results from the study, covering 12-16 weeks post-treatment initiation, indicate that 72.8% of patients achieved a "clear/almost clear" skin rating, with varying percentages reaching significant reductions in psoriasis severity scores (PASI75, PASI90, PASI100).* -
- Improvements in symptoms and quality of life were noted alongside a high treatment adherence rate of 90%, and while nine adverse events were recorded, the
Article Synopsis
- Real-world analysis evaluated the long-term benefits of brodalumab for treating moderate-to-severe psoriasis in 180 Greek patients over 24 months.
- The study showed significant improvements in psoriasis severity (measured by PASI scores) and quality of life (measured by DLQI scores) from baseline, with high proportions of patients achieving major reductions in PASI scores as early as 1 month into treatment.
- Overall, the findings support brodalumab's effectiveness in standard clinical practice, highlighting its rapid and sustained positive impact on patients' conditions.
Article Synopsis
- - Harlequin syndrome is a rare autonomic nervous system disorder that results in reduced facial flushing and sweating on one side, triggered by factors like exercise or stress.
- - The condition is linked to an issue in the cervical sympathetic nerves, specifically on the side that does not flush.
- - The text includes a case study of an 8-year-old with this syndrome and discusses other skin-related conditions that also use the term "harlequin."
Hidradenitis suppurativa and psoriasis are considered chronic inflammatory diseases suggesting the existence of common pathogenetic pathways. We present two cases of comorbid psoriasis and hidradenitis suppurativa, treated with certolizumab pegol and brodalumab due to failure of response to other conventional therapies. Monoclonal antibody therapies have revolutionized the treatment of chronic inflammatory disorders such as psoriasis and hidradenitis suppurativa.
View Article and Find Full Text PDF